Naltrexone for Early Problem Drinkers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00000455|
Recruitment Status : Completed
First Posted : November 3, 1999
Last Update Posted : June 20, 2011
Early problem drinkers are prevalent in the United States. Recent controlled trials have shown that brief interventions in the primary care setting can reduce drinking and alcohol-related problems in patients who lack evidence of alcohol dependence.
Although naltrexone (Revia) has been approved for the treatment of alcohol dependence, few pharmacotherapy studies have been undertaken with early problem drinkers. This study is an 8-week trial of naltrexone versus placebo, combined with coping skills treatment that either focuses on targeted use of medication or serves as background to daily use of the medication. A total of 160 early problem drinkers recruited through screening in primary care medical settings will be randomly assigned to one of four treatment groups. Followup evaluations will be conducted at the end of treatment and again 3, 6, and 12 months.
|Condition or disease||Intervention/treatment||Phase|
|Alcoholism||Drug: naltrexone||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||160 participants|
|Official Title:||Targeted Naltrexone for Early Problem Drinkers|
|Study Completion Date :||September 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000455
|United States, Pennsylvania|
|Department of Psychiatry, University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19103|